Unsubscribe Parkinson's At 03:38 PM 5/27/98 -0400, you wrote: >There are 17 messages totalling 1196 lines in this issue. > >Topics in this special issue: > > 1. falling (2) > 2. What's Really Important > 3. news > 4. importand news > 5. Zoloft Experience? (2) > 6. Petitions still available (2) > 7. Eye-problems > 8. imipramine (2) > 9. towards an understanding of falling (3) > 10. LOOKING FOR JERRY FINCH > 11. PubMed search results - PD - 30 days [1 of 2] > >---------------------------------------------------------------------- > >Date: Wed, 27 May 1998 11:35:56 EDT >From: DPYOTHERS <[log in to unmask]> >Subject: Re: falling > >Dear falling, >I just had a fall last week, from the family room to the garage, two steps and >I have a handle to hold too, but down I went. It's doing things too quickly >and I was in a hurry that day. I'm on Sinemet CR and Requip and have a hard >time with baalance and worrying about that next fall. I forget I have to >tell my feet to move, right-right-right. > >Patricia >61, 4 yrs. > >------------------------------ > >Date: Wed, 27 May 1998 11:43:02 -0400 >From: Gail Vass <[log in to unmask]> >Subject: What's Really Important > >~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ > What's Really Important > > A few years ago at the Seattle Special Olympics, nine >contestants, all physically or mentally disabled, assembled >at the starting line for the 100-yard dash. At the gun they >all started out, not exactly in a dash, but with the relish >to run the race to the finish and win. > All, that is, except one boy who stumbled on the asphalt, >tumbled over a couple of times, and began to cry. The other >eight heard the boy cry. They slowed down and paused. Then >they all turned around and went back. Every one of them. One >girl with Down's syndrome bent down and kissed him and said, >"This will make it better." Then all nine linked arms and >walked together to the finish line. > Everyone in the stadium stood, and the cheering went >on for 10 minutes. > > By Author Unknown > Submitted by Bob French > from A 3rd Serving of Chicken Soup for the Soul > Copyright 1996 by Jack Canfield and > Mark Victor Hansen > >A good reminder, > >Gail Vass >~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ > >------------------------------ > >Date: Wed, 27 May 1998 11:42:32 EDT >From: DeitzM <[log in to unmask]> >Subject: news > >This is a multi-part message in MIME format. > >--part0_896283752_boundary >Content-ID: <[log in to unmask]> >Content-type: text/plain; charset=US-ASCII > > >NEOTROFIN Reported to Stimulate Nerve Regeneration > > IRVINE, Calif.--(BUSINESS WIRE)-- May 21, 1998--NeoTherapeutics, Inc. >(Nasdaq: NEOT; NEOTW) announced today that researchers from North Carolina >and Canada reported that the Company's lead product candidate, AIT-082 >(NEOTROFIN(tm)), has been shown to stimulate nerve regeneration in tissue >culture and in animals. > > At the 6th International Symposium on Adenosine and Adenine Nucleotides, >held in Ferrara, Italy, Dr. Bernhard H.J. Juurlink of the Department of >Anatomy and Cell Biology at the University of Saskatchewan, Saskatoon, >Saskatchewan, Canada, reported that treatment of hippocampal neurons with >AIT-082 caused nerve outgrowth and enhanced branching of the nerve processes. >Hippocampal neurons have been reported to be involved in memory function. > > "Glutamate excitotoxicity is implicated in a number of neurodegenerative >diseases," Dr. Juurlink stated. "AIT-082 is potentially therapeutic in a >number of neurodegenerative disorders. We have demonstrated in hippocampal >neurons grown in culture that AIT-082 not only promotes neurite formation in >developing hippocampal neurons, but it prevents much of the neurite >degeneration following exposure to excessive amounts of the neurotransmitter >glutamate." > > Dr. Julio J. Ramirez, the R. Stuart Dickson Professor of Psychology, >Davidson College, Davidson, North Carolina, demonstrated in animals that >after destruction of a discreet area of the brain involved in memory, >treatment with AIT-082 caused re-growth of neurons into the damaged area. >These effects were seen after only four days of treatment with AIT-082. > > "Since the reorganization of brain circuitry has been shown to contribute >to recovery of memory function after injury or degeneration in areas crucial >to learning and memory," Dr. Ramirez stated, "the possibility that AIT-082 >might enhance this reorganization opens up marvelous opportunities to promote >recovery of function in injured and diseased brains." > > NeoTherapeutics is engaged in the discovery and development of drugs that >act on the central nervous system to repair nerve cells and treat >neurodegenerative diseases such as Alzheimer's disease, spinal cord injury, >Parkinson's disease and stroke, as well as other neurological conditions such >as migraine. NeoTherapeutics' products are orally administered and based >upon patented technologies. AIT-082 (NEOTROFIN(tm)) is currently in human >clinical trials for the treatment of Alzheimer's disease. For additional >company information, visit the NeoTherapeutics website at >www.neotherapeutics.com. > > This press release contains forward-looking statements regarding future >events and the future performance of NeoTherapeutics that involve risks and >uncertainties that could cause actual results to differ materially. These >risks include, but are not limited to, the biological activity, side effect >profile and efficacy of AIT-082, the early stage of product development, the >potential need for additional funding, the initiation and completion of >clinical trials and dependence on third parties for clinical testing, >manufacturing and marketing. These risks are described in further detail in >the Company's annual and quarterly reports filed with the Securities and >Exchange Commission. > >--part0_896283752_boundary >Content-ID: <[log in to unmask]> >Content-type: message/rfc822 >Content-transfer-encoding: 7bit >Content-disposition: inline > >From: Gregfmason <[log in to unmask]> >Return-path: <[log in to unmask]> >To: [log in to unmask] >Subject: PD Stuff >Date: Wed, 27 May 1998 02:22:59 EDT >Organization: AOL (http://www.aol.com) >Mime-Version: 1.0 >Content-type: text/plain; charset=US-ASCII >Content-transfer-encoding: 7bit > >Subj: NEOTROFIN Reported to Stimulate Nerve Regeneration >Date: 98-05-21 10:09:30 EDT >From: AOL News >BCC: Gregfmason > >NEOTROFIN Reported to Stimulate Nerve Regeneration > > IRVINE, Calif.--(BUSINESS WIRE)-- May 21, 1998--NeoTherapeutics, Inc. >(Nasdaq: NEOT; NEOTW) announced today that researchers from North Carolina >and Canada reported that the Company's lead product candidate, AIT-082 >(NEOTROFIN(tm)), has been shown to stimulate nerve regeneration in tissue >culture and in animals. > > At the 6th International Symposium on Adenosine and Adenine Nucleotides, >held in Ferrara, Italy, Dr. Bernhard H.J. Juurlink of the Department of >Anatomy and Cell Biology at the University of Saskatchewan, Saskatoon, >Saskatchewan, Canada, reported that treatment of hippocampal neurons with >AIT-082 caused nerve outgrowth and enhanced branching of the nerve processes. >Hippocampal neurons have been reported to be involved in memory function. > > "Glutamate excitotoxicity is implicated in a number of neurodegenerative >diseases," Dr. Juurlink stated. "AIT-082 is potentially therapeutic in a >number of neurodegenerative disorders. We have demonstrated in hippocampal >neurons grown in culture that AIT-082 not only promotes neurite formation in >developing hippocampal neurons, but it prevents much of the neurite >degeneration following exposure to excessive amounts of the neurotransmitter >glutamate." > > Dr. Julio J. Ramirez, the R. Stuart Dickson Professor of Psychology, >Davidson College, Davidson, North Carolina, demonstrated in animals that >after destruction of a discreet area of the brain involved in memory, >treatment with AIT-082 caused re-growth of neurons into the damaged area. >These effects were seen after only four days of treatment with AIT-082. > > "Since the reorganization of brain circuitry has been shown to contribute >to recovery of memory function after injury or degeneration in areas crucial >to learning and memory," Dr. Ramirez stated, "the possibility that AIT-082 >might enhance this reorganization opens up marvelous opportunities to promote >recovery of function in injured and diseased brains." > > NeoTherapeutics is engaged in the discovery and development of drugs that >act on the central nervous system to repair nerve cells and treat >neurodegenerative diseases such as Alzheimer's disease, spinal cord injury, >Parkinson's disease and stroke, as well as other neurological conditions such >as migraine. NeoTherapeutics' products are orally administered and based >upon patented technologies. AIT-082 (NEOTROFIN(tm)) is currently in human >clinical trials for the treatment of Alzheimer's disease. For additional >company information, visit the NeoTherapeutics website at >www.neotherapeutics.com. > > This press release contains forward-looking statements regarding future >events and the future performance of NeoTherapeutics that involve risks and >uncertainties that could cause actual results to differ materially. These >risks include, but are not limited to, the biological activity, side effect >profile and efficacy of AIT-082, the early stage of product development, the >potential need for additional funding, the initiation and completion of >clinical trials and dependence on third parties for clinical testing, >manufacturing and marketing. These risks are described in further detail in >the Company's annual and quarterly reports filed with the Securities and >Exchange Commission. > >--part0_896283752_boundary-- > >------------------------------ > >Date: Wed, 27 May 1998 11:44:38 EDT >From: DeitzM <[log in to unmask]> >Subject: importand news > >This is a multi-part message in MIME format. > >--part0_896283878_boundary >Content-ID: <[log in to unmask]> >Content-type: text/plain; charset=US-ASCII > > >NEOTROFIN Reported to Stimulate Nerve Regeneration > > IRVINE, Calif.--(BUSINESS WIRE)-- May 21, 1998--NeoTherapeutics, Inc. >(Nasdaq: NEOT; NEOTW) announced today that researchers from North Carolina >and Canada reported that the Company's lead product candidate, AIT-082 >(NEOTROFIN(tm)), has been shown to stimulate nerve regeneration in tissue >culture and in animals. > > At the 6th International Symposium on Adenosine and Adenine Nucleotides, >held in Ferrara, Italy, Dr. Bernhard H.J. Juurlink of the Department of >Anatomy and Cell Biology at the University of Saskatchewan, Saskatoon, >Saskatchewan, Canada, reported that treatment of hippocampal neurons with >AIT-082 caused nerve outgrowth and enhanced branching of the nerve processes. >Hippocampal neurons have been reported to be involved in memory function. > > "Glutamate excitotoxicity is implicated in a number of neurodegenerative >diseases," Dr. Juurlink stated. "AIT-082 is potentially therapeutic in a >number of neurodegenerative disorders. We have demonstrated in hippocampal >neurons grown in culture that AIT-082 not only promotes neurite formation in >developing hippocampal neurons, but it prevents much of the neurite >degeneration following exposure to excessive amounts of the neurotransmitter >glutamate." > > Dr. Julio J. Ramirez, the R. Stuart Dickson Professor of Psychology, >Davidson College, Davidson, North Carolina, demonstrated in animals that >after destruction of a discreet area of the brain involved in memory, >treatment with AIT-082 caused re-growth of neurons into the damaged area. >These effects were seen after only four days of treatment with AIT-082. > > "Since the reorganization of brain circuitry has been shown to contribute >to recovery of memory function after injury or degeneration in areas crucial >to learning and memory," Dr. Ramirez stated, "the possibility that AIT-082 >might enhance this reorganization opens up marvelous opportunities to promote >recovery of function in injured and diseased brains." > > NeoTherapeutics is engaged in the discovery and development of drugs that >act on the central nervous system to repair nerve cells and treat >neurodegenerative diseases such as Alzheimer's disease, spinal cord injury, >Parkinson's disease and stroke, as well as other neurological conditions such >as migraine. NeoTherapeutics' products are orally administered and based >upon patented technologies. AIT-082 (NEOTROFIN(tm)) is currently in human >clinical trials for the treatment of Alzheimer's disease. For additional >company information, visit the NeoTherapeutics website at >www.neotherapeutics.com. > > This press release contains forward-looking statements regarding future >events and the future performance of NeoTherapeutics that involve risks and >uncertainties that could cause actual results to differ materially. These >risks include, but are not limited to, the biological activity, side effect >profile and efficacy of AIT-082, the early stage of product development, the >potential need for additional funding, the initiation and completion of >clinical trials and dependence on third parties for clinical testing, >manufacturing and marketing. These risks are described in further detail in >the Company's annual and quarterly reports filed with the Securities and >Exchange Commission. > >--part0_896283878_boundary >Content-ID: <[log in to unmask]> >Content-type: message/rfc822 >Content-transfer-encoding: 7bit >Content-disposition: inline > >From: Gregfmason <[log in to unmask]> >Return-path: <[log in to unmask]> >To: [log in to unmask] >Subject: PD Stuff >Date: Wed, 27 May 1998 02:22:59 EDT >Organization: AOL (http://www.aol.com) >Mime-Version: 1.0 >Content-type: text/plain; charset=US-ASCII >Content-transfer-encoding: 7bit > >Subj: NEOTROFIN Reported to Stimulate Nerve Regeneration >Date: 98-05-21 10:09:30 EDT >From: AOL News >BCC: Gregfmason > >NEOTROFIN Reported to Stimulate Nerve Regeneration > > IRVINE, Calif.--(BUSINESS WIRE)-- May 21, 1998--NeoTherapeutics, Inc. >(Nasdaq: NEOT; NEOTW) announced today that researchers from North Carolina >and Canada reported that the Company's lead product candidate, AIT-082 >(NEOTROFIN(tm)), has been shown to stimulate nerve regeneration in tissue >culture and in animals. > > At the 6th International Symposium on Adenosine and Adenine Nucleotides, >held in Ferrara, Italy, Dr. Bernhard H.J. Juurlink of the Department of >Anatomy and Cell Biology at the University of Saskatchewan, Saskatoon, >Saskatchewan, Canada, reported that treatment of hippocampal neurons with >AIT-082 caused nerve outgrowth and enhanced branching of the nerve processes. >Hippocampal neurons have been reported to be involved in memory function. > > "Glutamate excitotoxicity is implicated in a number of neurodegenerative >diseases," Dr. Juurlink stated. "AIT-082 is potentially therapeutic in a >number of neurodegenerative disorders. We have demonstrated in hippocampal >neurons grown in culture that AIT-082 not only promotes neurite formation in >developing hippocampal neurons, but it prevents much of the neurite >degeneration following exposure to excessive amounts of the neurotransmitter >glutamate." > > Dr. Julio J. Ramirez, the R. Stuart Dickson Professor of Psychology, >Davidson College, Davidson, North Carolina, demonstrated in animals that >after destruction of a discreet area of the brain involved in memory, >treatment with AIT-082 caused re-growth of neurons into the damaged area. >These effects were seen after only four days of treatment with AIT-082. > > "Since the reorganization of brain circuitry has been shown to contribute >to recovery of memory function after injury or degeneration in areas crucial >to learning and memory," Dr. Ramirez stated, "the possibility that AIT-082 >might enhance this reorganization opens up marvelous opportunities to promote >recovery of function in injured and diseased brains." > > NeoTherapeutics is engaged in the discovery and development of drugs that >act on the central nervous system to repair nerve cells and treat >neurodegenerative diseases such as Alzheimer's disease, spinal cord injury, >Parkinson's disease and stroke, as well as other neurological conditions such >as migraine. NeoTherapeutics' products are orally administered and based >upon patented technologies. AIT-082 (NEOTROFIN(tm)) is currently in human >clinical trials for the treatment of Alzheimer's disease. For additional >company information, visit the NeoTherapeutics website at >www.neotherapeutics.com. > > This press release contains forward-looking statements regarding future >events and the future performance of NeoTherapeutics that involve risks and >uncertainties that could cause actual results to differ materially. These >risks include, but are not limited to, the biological activity, side effect >profile and efficacy of AIT-082, the early stage of product development, the >potential need for additional funding, the initiation and completion of >clinical trials and dependence on third parties for clinical testing, >manufacturing and marketing. These risks are described in further detail in >the Company's annual and quarterly reports filed with the Securities and >Exchange Commission. > >--part0_896283878_boundary-- > >------------------------------ > >Date: Wed, 27 May 1998 11:44:51 EDT >From: DPYOTHERS <[log in to unmask]> >Subject: Re: Zoloft Experience? > >Ron: >I have been taking Zoloft for some time now, 150 mg. It does help the blues >but makes things steady and non committal feelings abound, but sometimes you >need that. > >Patricia > >61,4 yrs. > >------------------------------ > >Date: Wed, 27 May 1998 11:47:01 EDT >From: KMCRAE <[log in to unmask]> >Subject: Re: Zoloft Experience? > >Ken has been taking zoloft for several years with no noticeable side effects. >I t does seem to hold his tendency to depression in check. Barbara Smith, >CG/Ken/70/17 > >------------------------------ > >Date: Wed, 27 May 1998 11:55:59 EDT >From: DeitzM <[log in to unmask]> >Subject: Petitions still available > >Do you have your petitons? If not send via email name and home address and it >will be in the next mail. > > >Helen Mason [log in to unmask] > >------------------------------ > >Date: Wed, 27 May 1998 12:02:13 -0500 >From: MRS BEV K STEWARD <[log in to unmask]> >Subject: Re: falling > >Barb, > >Have you been to a neurologist who is a movement specialist? If not, >I'd sure recommend it in order to pin down the possibility of a >Parkinson Plus sydrome. (closely related but not PD). > >Bev > >------------------------------ > >Date: Wed, 27 May 1998 17:10:36 UT >From: Barbara Mallut <[log in to unmask]> >Subject: Re: Eye-problems > >Camilla, and All... > >The good news and the bad news: > >First the good news: > >Taking the "PD eye problem" a bit further, our List-sis, >Gail Vass, had emailed me a copy of a message >posted on the Sjogren's Syndrome List with the best >eye-drop-advice I've had yet. > >FYI... Sjogren's Syndrome is an arthritis-related >Autoimmune disease that effects the eyes terribly! If >ANYONE knows about eyes and disease-caused eye >problems, it's Sjogren's suffers! > >The Sjogren's-list-folks recommend the use of >"Refresh Plus" lubricant eye drops made by >Allergan, which has NO PRESERVATIVES. This >last NON-ingredient is very important as far as your >comfort level and unfortunately, it seems all over- >the-counter eye drops DO have preservatives >EXCEPT for the "Refresh Plus" brand. > >The reason this brand can omit preservatives is >because EACH dose of eye drops is individually >packaged in single-dose, disposable plastic container. >THAT makes a world of difference in your comfort >level and your eyes'll thank ya for it 'cause they'll feel >SOOOO good after a shot of Refresh Plus - I'm using > the product now and it's GREAT! TOTAL eye comfort! > >The bad news: > >Thirty individually packaged doses of Refresh plus >(one box of 30) cost $9.95! I use eye drops twice >a day, minimum (used 'em much MORE prior to >changing over to the Refresh Plus product), and this >is just beyond my means on an ongoing basis. >I suspect most other PWPs will feel the same >about the cost. > >More "bad news" > >I don't happen to have a tremor so it's not TOO tough >for me to pick up, hold, and squeeze the smallish >individual-dose Fresh Plus containers. However, I >can easily see where a Parkie WITH a tremor coming >close to putting an eye out trying to hold and squeeze >those small individual-dose containers. > >NONE-THE-LESS... this product DOES bring >SIGNIFICANT relief to painful, stinging ,oh-so-dry >eyes, so IF ya can, I'd suggest trying it. > >Barb Mallut >[log in to unmask] > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > > >---------- >From: Parkinson's Information Exchange on behalf of Camilla H.Flintermann >Sent: Wednesday, May 27, 1998 7:40 AM >To: Multiple recipients of list PARKINSN >Subject: Re: Eye-problems > >YES! this, or a variation "eye scrub" of the lids, is standard RX for the >blepharitis that plagues PWPs. Peter has also found it helpful, and we try >to remember to use "artificial tears" As drops a few times a day to combat >the dryness. > > > >>on the advice of my eye doctor, several times a day, i add a few drops of >>BABY shampoo to a cup of warm water and soak my eyes with a tissue that >>has been dipped into the solution.,, been doing it for over a year... >> all i have to do is get complacent and skip a few days and the crusties >>and potential for an irritating stie return... it may help others as well. >> >> >> >>Dale Williams >>[log in to unmask] > > > Camilla Flintermann, CG for Peter 80/9 > Oxford, OH > [log in to unmask] >"http://www.newcountry.nu/pd/members/camilla/one.htm" My Home Page > > * * * * * * * * * * * * * * * * * > * Ask me about the CARE list for* > * Parkinson's caregivers ! * > * * * * * * * * * * * * * * * * * > >------------------------------ > >Date: Wed, 27 May 1998 10:02:36 -0700 >From: Jim Jameson <[log in to unmask]> >Subject: imipramine > >I take 20mg in the morning and 20mg at night of imipramine, for depression >and have not seen much relief except it seems to keep me tired all the >time. >I keep hearing about zoloft does anyone know if that is better and makes >you less >tired all the time. >also I have been on amantadine for four months and it seems to help with >the >tremors a slight amount. I take 10mg in the morning and 10 at night. I have >been >on sinemet for four years at max dose twice a day have never seen much for >that >one. I also take selegelline twice a day.. the only thing that has shown >me anything >is this amantadine. I use to take permax however it almost shut down my >kidneys.. >Does anyone have better suggestions? > >Jim J. 54/4 >[log in to unmask] > >P.S. I love all the information on the list > >------------------------------ > >Date: Wed, 27 May 1998 13:17:06 -0400 >From: Tom Riess <[log in to unmask]> >Subject: towards an understanding of falling > >Dear Barbara, > >You said you were unclear as to whether festination is a symptom of PD or= > a >side effect of the meds. > >This is unclear to everyone but let me offer my opinion. Festination li= >ke >dyskinesia is not a side effect of medication but rather is a symptom of >basic PD pathology which is manifested in the presence of exogenous >dopamine. Furthermore, this pathology is actually a visual perceptive or= > >vision processing problem. The same pathology in the absence of dopamine= > = > >manifests itself as akinesia. So I would speculate that akinesia and >dyskinesia are two sides of the same coin and the side that is "up" is a >function of medication level. Manipulating various parameters of vision c= >an >impact on akinesia, dyskinesia and festination and ultimately falling as >well. > >regards, > >Tom > >------------------------------ > >Date: Wed, 27 May 1998 13:22:34 EDT >From: Elizabeth Southwood <[log in to unmask]> >Subject: Re: LOOKING FOR JERRY FINCH > >I've emailed Jerry Finch ([log in to unmask]) and not had any answer re changes in >my website as requested but the emails have not been returned. Liz S~~ > >------------------------------ > >Date: Wed, 27 May 1998 13:39:59 -0400 >From: Gail Vass <[log in to unmask]> >Subject: Re: imipramine > >Jim, >Have you been seen by a Movement Disorder Specialist who specializes in >Parkinsons and have your meds evaluated by them? >Your cyber sis, >Gail Vass email address [log in to unmask] > >------------------------------ > >Date: Wed, 27 May 1998 12:27:47 -0600 >From: Nancy Burnham <[log in to unmask]> >Subject: Re: Petitions still available > >Received my copy yesterday. When do you need them back? Nancy B >-----Original Message----- >From: DeitzM <[log in to unmask]> >To: Multiple recipients of list PARKINSN <[log in to unmask]> >Date: Wednesday, May 27, 1998 10:00 AM >Subject: Petitions still available > > >>Do you have your petitons? If not send via email name and home address and >it >>will be in the next mail. >> >> >>Helen Mason [log in to unmask] >> > >------------------------------ > >Date: Wed, 27 May 1998 15:20:42 EDT >From: William Heitman <[log in to unmask]> >Subject: Re: towards an understanding of falling > >In a message dated 5/27/98 12:22:19 PM Central Daylight Time, >[log in to unmask] writes: > ><< > You said you were unclear as to whether festination is a symptom of PD or a > side effect of the meds. > >> >I believe Dr Parkinson described a patient who hired a guy to walk ahead of >him and stop him when he got to going too fast. If so, that patient was >festinating long before the advent of L-Dopa therapy. I am almost certain >that it is a function of the disease. > >Regards, >WHH 54/18 > >------------------------------ > >Date: Wed, 27 May 1998 15:24:23 EDT >From: Krishna Ayala <[log in to unmask]> >Subject: Re: towards an understanding of falling > >Dear Tom, > >I found your opinion regarding akinesia and dyskinesia as connected with >vision rather interesting. You say you could use your visual perceptions >to control dyskinesia and akinesia. > >Could you be more specific as to how one can use our visual perceptions >to control dyskinesia? > >regards >kris > >e-mail [log in to unmask] > > >______________________________________________________ >Get Your Private, Free Email at http://www.hotmail.com > >------------------------------ > >Date: Wed, 27 May 1998 15:38:09 EDT >From: Janet Paterson <[log in to unmask]> >Subject: PubMed search results - PD - 30 days [1 of 2] > >Parkinson's Disease - 164 citations found - 98/05/27 - 30 days - PubMed > > Spillantini MG, et al. >alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's >disease and dementia with Lewy bodies. >Proc Natl Acad Sci U S A. 1998 May 26; 95(11): 6469-6473. >PMID: 9600990. > > Wakabayashi K, et al. >Apolipoprotein E epsilon4 allele and progression of cortical Lewy body >pathology in Parkinson's disease. >Acta Neuropathol (Berl). 1998 May; 95(5): 450-454. >PMID: 9600590; UI: 98261217. > > Good PF, et al. >Protein nitration in Parkinson's disease. >J Neuropathol Exp Neurol. 1998 Apr; 57(4): 338-342. >PMID: 9600227; UI: 98260854. > > Irizarry MC, et al. >Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's >disease and cortical Lewy body disease contain alpha-synuclein >immunoreactivity. >J Neuropathol Exp Neurol. 1998 Apr; 57(4): 334-337. >PMID: 9600226; UI: 98260853. > > Hansen LA, et al. >Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's >disease and dementia. >J Neurol Neurosurg Psychiatry. 1998 May; 64(5): 653-656. >PMID: 9598683; UI: 98258630. > > Colzi A, et al. >Continuous subcutaneous waking day apomorphine in the long term treatment of >levodopa induced interdose dyskinesias in Parkinson's disease. >J Neurol Neurosurg Psychiatry. 1998 May; 64(5): 573-576. >PMID: 9598668; UI: 98258615. > > Liu EH, et al. >Persistent perioperative laryngospasm in a patient with Parkinson's disease. >Can J Anaesth. 1998 May; 45(5 Pt 1): 495. No abstract available. >PMID: 9598268; UI: 98260630. > > Uitti RJ. >Medical treatment of essential tremor and Parkinson's disease. >Geriatrics. 1998 May; 53(5): 46-48. >PMID: 9597979; UI: 98260270. > > Uitti RJ. >Tremor: how to determine if the patient has Parkinson's disease. >Geriatrics. 1998 May; 53(5): 30-36. >PMID: 9597978; UI: 98260269. > > Quinn N, et al. >Functional neurosurgery for Parkinson's disease. Has come a long way, though >much remains experimental. >BMJ. 1998 Apr 25; 316(7140): 1259-1260. No abstract available. >PMID: 9554893; UI: 98223565. > > Davidson WS, et al. >Stabilization of alpha-synuclein secondary structure upon binding to synthetic >membranes. >J Biol Chem. 1998 Apr 17; 273(16): 9443-9449. >PMID: 9545270; UI: 98211967. > > Cadet JL, et al. >Free radicals and the pathobiology of brain dopamine systems. >Neurochem Int. 1998 Feb; 32(2): 117-131. Review. >PMID: 9542724; UI: 98203852. > > Factor SA, et al. >'Sleep benefit' in Parkinson's disease. >Neurology. 1998 May; 50(5): 1514-1515. No abstract available. >PMID: 9596032; UI: 98255471. > > Checkoway H, et al. >A genetic polymorphism of MAO-B modifies the association of cigarette smoking >and Parkinson's disease. >Neurology. 1998 May; 50(5): 1458-1461. >PMID: 9596006; UI: 98255445. > > Factor SA, et al. >Acute delirium after withdrawal of amantadine in Parkinson's disease. >Neurology. 1998 May; 50(5): 1456-1458. >PMID: 9596005; UI: 98255444. > > Gorell JM, et al. >The risk of Parkinson's disease with exposure to pesticides, farming, well >water, and rural living. >Neurology. 1998 May; 50(5): 1346-1350. >PMID: 9595985; UI: 98255424. > > Hogl BE, et al. >A clinical, pharmacologic, and polysomnographic study of sleep benefit in >Parkinson's disease. >Neurology. 1998 May; 50(5): 1332-1339. >PMID: 9595983; UI: 98255422. > > Growdon JH, et al. >Levodopa improves motor function without impairing cognition in mild non- >demented Parkinson's disease patients. Parkinson Study Group. >Neurology. 1998 May; 50(5): 1327-1331. >PMID: 9595982; UI: 98255421. > > Verhagen Metman L, et al. >Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's >disease. >Neurology. 1998 May; 50(5): 1323-1326. >PMID: 9595981; UI: 98255420. > > Goetz CG. >New lessons from old drugs: amantadine and Parkinson's disease. >Neurology. 1998 May; 50(5): 1211-1212. No abstract available. >PMID: 9595964; UI: 98255403. > > Greene SM, et al. >Symptom study in context: effects of marital quality on signs of Parkinson's >disease during patient-spouse interaction. >Psychiatry. 1998; 61(1): 35-45. >PMID: 9595594; UI: 98257950. > > Castro ME, et al. >5-HT1B receptor binding in degenerative movement disorders. >Brain Res. 1998 Apr 20; 790(1-2): 323-328. >PMID: 9593971. > > Schapira AHV. >Human complex I defects in neurodegenerative diseases. >Biochim Biophys Acta. 1998 May 6; 1364(2): 261-270. >PMID: 9593927. > > Walker DG, et al. >Expression of the proto-oncogene Ret, a component of the GDNF receptor >complex, persists in human substantia nigra neurons in Parkinson's disease. >Brain Res. 1998 May 11; 792(2): 207-217. >PMID: 9593897. > > Gomez-Vargas M, et al. >Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and >inhibits lipid peroxidation in different regions of the rat brain. >Brain Res. 1998 Apr 20; 790(1-2): 202-208. >PMID: 9593894. > > Van Muiswinkel FL, et al. >Sustained pharmacological inhibition of nitric oxide synthase does not affect >the survival of intrastriatal rat fetal mesencephalic transplants. >Brain Res. 1998 May 4; 792(1): 48-58. >PMID: 9593818. > > Fischman AJ, et al. >Rapid detection of Parkinson's disease by SPECT with altropane: a selective >ligand for dopamine transporters. >Synapse. 1998 Jun; 29(2): 128-141. >PMID: 9593103; UI: 98253935. > > Madras BK, et al. >Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human >dopamine transporter in postmortem normal and Parkinson's diseased brain. >Synapse. 1998 Jun; 29(2): 116-127. >PMID: 9593102; UI: 98253934. > > Baldi I, et al. >[No title available]. >Rev Epidemiol Sante Publique. 1998 Mar; 46(2): 134-142. French. >PMID: 9592856; UI: 98255214. > > Hubble JP, et al. >Gene-toxin interaction as a putative risk factor for Parkinson's disease with >dementia. >Neuroepidemiology. 1998; 17(2): 96-104. >PMID: 9592786; UI: 98255144. > > Ubeda JV. >Null hypothesis of husband-wife concordance of Parkinson's disease in 1,000 >married couples over age 50 in Spain. >Neuroepidemiology. 1998; 17(2): 90-95. >PMID: 9592785; UI: 98255143. > > Mandel RJ, et al. >Characterization of Intrastriatal Recombinant Adeno-Associated Virus-Mediated >Gene Transfer of Human Tyrosine Hydroxylase and Human GTP-Cyclohydrolase I in >a Rat Model of Parkinson's Disease. >J Neurosci. 1998 Jun 1; 18(11): 4271-4284. >PMID: 9592104. > > Kotake Y, et al. >Deprenyl decreases an endogenous parkinsonism-inducing compound, >1-benzyl-1,2,3,4-tetra-hydro-isoquinoline in mice: in vivo and in vitro >studies. >Brain Res. 1998 Mar 23; 787(2): 341-343. >PMID: 9518683; UI: 98186768. > > Baas H, et al. >Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing >off" phenomenon and levodopa requirements in fluctuating parkinsonian >patients. >Neurology. 1998 May; 50(5 Suppl 5): S46-S53. >PMID: 9591522; UI: 98252196. > > Waters CH, et al. >Tolcapone in stable Parkinson's disease: efficacy and safety of long-term >treatment. Tolcapone Stable Study Group. >Neurology. 1998 May; 50(5 Suppl 5): S39-S45. >PMID: 9591521; UI: 98252195. > > Jorga KM. >Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of >early studies in volunteers. >Neurology. 1998 May; 50(5 Suppl 5): S31-S38. >PMID: 9591520; UI: 98252194. > > Goetz CG. >Influence of COMT inhibition on levodopa pharmacology and therapy. >Neurology. 1998 May; 50(5 Suppl 5): S26-S30. >PMID: 9591519; UI: 98252193. > > Chase TN. >Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. >Neurology. 1998 May; 50(5 Suppl 5): S17-S25. >PMID: 9591518; UI: 98252192. > > Goetz CG. >Highlights of the North American and European experiences. >Neurology. 1998 May; 50(5 Suppl 5): S15-S16. >PMID: 9591517; UI: 98252191. > > Kurth MC, et al. >COMT inhibition: a new treatment strategy for Parkinson's disease. >Neurology. 1998 May; 50(5 Suppl 5): S3-S14. >PMID: 9591516; UI: 98252190. > > Fahn S. >Tolcapone: COMT inhibition for the treatment of Parkinson's disease. >Neurology. 1998 May; 50(5 Suppl 5): S1-S2. No abstract available. >PMID: 9591515; UI: 98252189. > > Lindner MD, et al. >Therapeutic potential of a polymer-encapsulated L-DOPA and dopamine-producing >cell line in rodent and primate models of Parkinson's disease. >Cell Transplant. 1998 Mar; 7(2): 165-174. >PMID: 9588598; UI: 98248012. > > Othberg AI, et al. >Trophic effect of porcine sertoli cells on rat and human ventral mesencephalic >cells and HNT neurons in vitro. >Cell Transplant. 1998 Mar; 7(2): 157-164. >PMID: 9588597; UI: 98248011. > > Bakay RA, et al. >Immunological responses to injury and grafting in the central nervous system >of nonhuman primates. >Cell Transplant. 1998 Mar; 7(2): 109-120. >PMID: 9588593; UI: 98248007. > > Vidal N, et al. >Morphological and functional evidence for enhanced growth and potassium-evoked >dopamine release in striatal grafts innervated with a patchy growth pattern. >An in oculo nigrostriatal cograft study. >Cell Transplant. 1998 Mar; 7(2): 97-108. >PMID: 9588592; UI: 98248006. > > Blanco L, et al. >[No title available]. >Rev Neurol. 1998 Mar; 26(151): 361-365. Spanish. >PMID: 9585942; UI: 98247034. > > Fox SH, et al. >Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona >reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. >Exp Neurol. 1998 May; 151(1): 35-49. >PMID: 9582253; UI: 98250832. > > Mercuri NB, et al. >Modification of levodopa responses by deprenyl (selegiline): an electro- >physiological and behavioral study in the rat relevant to Parkinson's disease. >Ann Neurol. 1998 May; 43(5): 613-617. >PMID: 9585355; UI: 98244754. > > Murer MG, et al. >Chronic levodopa is not toxic for remaining dopamine neurons, but instead >promotes their recovery, in rats with moderate nigrostriatal lesions. >Ann Neurol. 1998 May; 43(5): 561-575. >PMID: 9585350; UI: 98244749. > > Uhl GR. >Hypothesis: the role of dopaminergic transporters in selective vulnerability >of cells in Parkinson's disease. >Ann Neurol. 1998 May; 43(5): 555-560. Review. No abstract available. >PMID: 9585349; UI: 98244748. > > Fahn S. >Welcome news about levodopa, but uncertainty remains. >Ann Neurol. 1998 May; 43(5): 551-554. No abstract available. >PMID: 9585348; UI: 98244747. > > Zawada WM, et al. >Somatic cell cloned transgenic bovine neurons for transplantation in >parkinsonian rats. >Nat Med. 1998 May; 4(5): 569-574. >PMID: 9585230; UI: 98244629. > > Lloyd GK, et al. >The potential of subtype-selective neuronal nicotinic acetylcholine receptor >agonists as therapeutic agents. >Life Sci. 1998; 62(17-18): 1601-1606. >PMID: 9585143; UI: 98244542. > > Pacchetti C, et al. >Active music therapy and Parkinson's disease: methods. >Funct Neurol. 1998 Jan; 13(1): 57-67. >PMID: 9584875; UI: 98244266. > > Nutt JG. >New pharmacological and surgical therapies for Parkinson's disease. >West J Med. 1998 Apr; 168(4): 267-268. No abstract available. >PMID: 9584671; UI: 98245650. > > Ben-Shlomo Y, et al. >Investigation by Parkinson's Disease Research Group of United Kingdom into >excess mortality seen with combined levodopa and selegiline treatment in >patients with early, mild Parkinson's disease: further results of randomised >trial and confidential inquiry. >BMJ. 1998 Apr 18; 316(7139): 1191-1196. >PMID: 9583926; UI: 98245965. > > Blaszczyk JW. >Motor deficiency in Parkinson's disease. >Acta Neurobiol Exp (Warsz). 1998; 58(1): 79-93. >PMID: 9583191; UI: 98244026. > > Davey GP, et al. >Energy Thresholds in Brain Mitochondria. Potential involvement in >neurodegeneration. >J Biol Chem. 1998 May 22; 273(21): 12753-12757. >PMID: 9582300. > > Abrams KR. >Monitoring randomised controlled trials. Parkinson's disease trial illustrates >the dangers of stopping early. >BMJ. 1998 Apr 18; 316(7139): 1183-1184. No abstract available. >PMID: 9552993; UI: 98221041. > > Breteler MM. >Selegiline, or the problem of early termination of clinical trials. The >clinical questions are not well answered, and probably never will be. >BMJ. 1998 Apr 18; 316(7139): 1182-1183. No abstract available. >PMID: 9552992; UI: 98221040. > > Vaughan JR, et al. >Sequencing of the alpha-synuclein gene in a large series of cases of familial >Parkinson's disease fails to reveal any further mutations. The European >Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD). >Hum Mol Genet. 1998 Apr; 7(4): 751-753. >PMID: 9499430; UI: 98167862. > > Castano A, et al. >Lipopolysaccharide intranigral injection induces inflammatory reaction and >damage in nigrostriatal dopaminergic system. >J Neurochem. 1998 Apr; 70(4): 1584-1592. >PMID: 9580157; UI: 98181720. > > Gage FH. >Cell therapy. >Nature. 1998 Apr 30; 392(6679 Suppl): 18-24. Review. >PMID: 9579857; UI: 98239460. > > Merello M, et al. >Changes in the motor response to acute L-dopa challenge after unilateral >microelectrode-guided posteroventral pallidotomy. >Clin Neuropharmacol. 1998 Mar; 21(2): 135-138. >PMID: 9579303; UI: 98240466. > > Nacasch N, et al. >Clozapine for the treatment of agitated-depressed patients with cognitive >impairment: a report of three cases. >Clin Neuropharmacol. 1998 Mar; 21(2): 132-134. >PMID: 9579302; UI: 98240465. > > Lyons KE, et al. >Gender differences in Parkinson's disease. >Clin Neuropharmacol. 1998 Mar; 21(2): 118-121. >PMID: 9579298; UI: 98240461. > > Bedard MA, et al. >Attentional deficits in Parkinson's disease: partial reversibility with >naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. >Clin Neuropharmacol. 1998 Mar; 21(2): 108-117. >PMID: 9579297; UI: 98240460. > > Brooks DJ, et al. >A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole >dopaminergic therapy in Parkinson's disease. >Clin Neuropharmacol. 1998 Mar; 21(2): 101-107. >PMID: 9579296; UI: 98240459. > > Sternic N, et al. >The therapeutic effect of moclobemide, a reversible selective monoamine >oxidase a inhibitor, in Parkinson's disease. >Clin Neuropharmacol. 1998 Mar; 21(2): 93-96. >PMID: 9579294; UI: 98240457. > > Baas H, et al. >Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian >patients with end-of-dose motor fluctuations. >Clin Neuropharmacol. 1998 Mar; 21(2): 86-92. >PMID: 9579293; UI: 98240456. > > Kuno S, et al. >Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP- >treated cynomolgus monkeys. >Clin Neuropharmacol. 1998 Jan; 21(1): 35-40. >PMID: 9579283; UI: 98240446. > > Brefel C, et al. >Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. >Br J Clin Pharmacol. 1998 Apr; 45(4): 412-415. >PMID: 9578193; UI: 98237304. > > Seitz G, et al. >Ascorbic acid stimulates DOPA synthesis and tyrosine hydroxylase gene >expression in the human neuroblastoma cell line SK-N-SH. >Neurosci Lett. 1998 Mar 6; 244(1): 33-36. >PMID: 9578138; UI: 98237249. > > Praamstra P, et al. >Evidence for lateral premotor and parietal overactivity in Parkinson's disease >during sequential and bimanual movements. A PET study. >Brain. 1998 Apr; 121( Pt 4): 769-772. No abstract available. >PMID: 9577401; UI: 98238262. > > Majsak MJ, et al. >The reaching movements of patients with Parkinson's disease under self- >determined maximal speed and visually cued conditions. >Brain. 1998 Apr; 121( Pt 4): 755-766. >PMID: 9577399; UI: 98238260. > > Johnson KA, et al. >Bimanual co-ordination in Parkinson's disease. >Brain. 1998 Apr; 121( Pt 4): 743-753. >PMID: 9577398; UI: 98238259. > > Alberts JL, et al. >The co-ordination and phasing of a bilateral prehension task. The influence of >Parkinson's disease. >Brain. 1998 Apr; 121( Pt 4): 725-742. >PMID: 9577397; UI: 98238258. > > Scott R, et al. >Neuropsychological, neurological and functional outcome following pallidotomy >for Parkinson's disease. A consecutive series of eight simultaneous bilateral >and twelve unilateral procedures. >Brain. 1998 Apr; 121( Pt 4): 659-675. >PMID: 9577392; UI: 98238253. > > Inzelberg R, et al. >Auditory hallucinations in Parkinson's disease. >J Neurol Neurosurg Psychiatry. 1998 Apr; 64(4): 533-535. >PMID: 9576549; UI: 98236086. > > Hayes AE, et al. >Toward a functional analysis of the basal ganglia. >J Cogn Neurosci. 1998 Mar; 10(2): 178-198. >PMID: 9555106; UI: 98223722. > > Zawada WM, et al. >Growth factors improve immediate survival of embryonic dopamine neurons after >transplantation into rats. >Brain Res. 1998 Mar 9; 786(1-2): 96-103. >PMID: 9554968; UI: 98223483. > > Masalha R, et al. >Selective dopamine neurotoxicity by an industrial chemical: an environmental >cause of Parkinson's disease? 1. [Brain research 774 (1997) 260-264]. >Brain Res. 1998 Mar 2; 785(2): 359. No abstract available. >PMID: 9518694; UI: 98186720. > > de la Monte SM, et al. >P53- and CD95-associated apoptosis in neurodegenerative diseases. >Lab Invest. 1998 Apr; 78(4): 401-411. >PMID: 9564885; UI: 98224556. > > Kelly MA, et al. >Locomotor activity in D2 dopamine receptor-deficient mice is determined by >gene dosage, genetic background, and developmental adaptations. >J Neurosci. 1998 May 1; 18(9): 3470-3479. >PMID: 9547254; UI: 98213724. > > Azizi SA, et al. >Engraftment and migration of human bone marrow stromal cells implanted in the >brains of albino rats--similarities to astrocyte grafts. >Proc Natl Acad Sci U S A. 1998 Mar 31; 95(7): 3908-3913. >PMID: 9520466; UI: 98188303. > > Almeida A, et al. >A rapid method for the isolation of metabolically active mitochondria from rat >neurons and astrocytes in primary culture. >Brain Res Brain Res Protoc. 1998 Mar; 2(3): 209-214. >PMID: 9507134; UI: 98176023. > >continued in part two.... > >janet paterson aka calendar control supervisor >51/10 - sinemet/selegiline/prozac - [log in to unmask] >quotations: http://newww.com/cgi-bin/do_cal?c:newvoice >pwp event calendar: http://newww.com/cgi-bin/do_cal?c:pwpc > >------------------------------ > >End of PARKINSN Digest - 27 May 1998 - Special issue >**************************************************** > >